Conclusions: Two pharmacogenetic associations previously reported with MMF were found in a population of 189 renal transplant patients treated with EC-MPS.
Introduction
The enteric-coated formulation of mycophenolate sodium (EC-MPS) has been developed with the aim of improving the gastro-intestinal tolerability of mycophenolic acid (MPA). Contrary to mycophenolate mofetil (MMF) for which many studies on potential associations between pharmacogenetics and pharmacokinetic or pharmacodynamic characteristics have been performed, no such study had been reported for EC-MPS so far.
Due to its particular formulation, the absorption phase of EC-MPS is different from that of MMF. Indeed, for EC-MPS the delayed absorption of MPA results in delayed entero-hepatic recirculation and subsequently higher and more variable MPA trough levels compared with MMF [1] . However, there are no differences regarding their inhibitory effect on inosine mono-phosphate dehydrogenases (IMPDH) I and II, two enzymes involved in the de novo purine synthesis [2] . MPA is metabolized by glucuronidation in a major, inactive metabolite, mycophenolate-phenyl-glucuronide (MPAG). This reaction is catalyzed by UDPglucuronosyl-transferases (UGT), particularly UGT1A9 in the kidney and the liver and UGT1A8 in intestinal cells [3, 4] . UGT2B7 produces a minor metabolite, mycophenolateacyl-glucuronide (AcMPAG) [5] , which is highly reactive [6] and might be implicated in adverse events, although not in MPA activity [7] . MPAG is mainly eliminated by the kidney [8] , probably involving the MRP2 drug transporter [9] . However, it is also subject to biliary excretion by the active, vectorial transport system OATP and MRP2 [10, 11] . Part of MPAG then undergoes bacterial deglucuronidation in the intestine back to MPA, which is then reabsorbed [8] giving rise to MPA entero-hepatic cycling.
Many association studies have been performed between SNPs in genes coding MPA metabolism (UGTs), transport (MRP2 and OATPs) or target proteins (IMPDH) on the one hand, and biopsy-proven acute rejection (BPAR) or the most frequent adverse effects of MPA (diarrhea, anemia and leucopenia) on the other hand. However, these studies were all conducted with MMF as the administered drug and lead to contradictories results [12] [13] [14] .
Moreover, none considered all these different genes simultaneously.
Recently, Jacobson et al observed in 978 renal transplants that single-nucleotide polymorphisms in interleukin IL 12A (IL12A; rs568408 G>A), cytochrome P450 (CYP) 2C8 (CYP2C8; rs11572076 G>A), and checkpoint homolog protein (HUS1; rs1056663 C>T) were associated with the occurrence of mycophenolic acid (MPA)-related anemia but not leucopenia [15] . Similarly, Bouamar et al observed in the fixed-dose group of the FDCC study (n=178) that the CYP2C8 (rs11572076 G>A) variant allele was significantly associated with an increased risk of anemia and leucopenia [16] .
The present work aimed at studying the effect of SNPs in MPA target, metabolism and transport proteins on BPAR, diarrhea, anemia and leucopenia in adult kidney transplant recipients on EC-MPS.
Methods

Patients and data
Patients (n=189) of the DOMINOS study [17] were enrolled in this sub-study after they had signed a specific written informed consent for the pharmacogenetic analyses involved. Briefly, in this study adult renal transplant patients treated with cyclosporine (CsA) and EC-MPS received 2160 mg/day MPS from the day of transplantation to week 6, and then the dose was reduced to 1440 mg/day. Cyclosporine concentration was adjusted based on C2 blood levels. Patients were randomized into two arms: one with steroid avoidance (patients only received 250 mg intravenous methylprednisolone on day 0 and 1) and a control group where patients received corticosteroids until the third month posttransplantation, after which the physician had the possibility to stop. At month 6, 38.1% and 86.6% of the patient actually received corticosteroids in the steroid avoidance and the control groups, respectively. Study visits were performed on days 1, 3, 5 and 7, weeks 2 and 4 and months 3 and 6 posttransplantation and laboratory test results (leukocyte counts, hemoglobin levels), CsA C2 levels, steroid and EC-MPS doses were collected. A kidney biopsy was performed in case of suspected rejection, and a blinded central review of all biopsy samples was performed at the end of the study. In the present study, we considered as BPAR biopsies with evidence of cellular acute rejection or with borderline lesions. In order to exclude the variability in the definition of diarrhea, only the diarrhea episodes leading to EC-MPS dose reduction or prolonged hospitalization were considered. Mycophenolate-related anemia was defined as the use of mycophenolic acid for at least 14 days prior to a hemoglobin level <10g/dL and/or initiation of erythropoietin therapy within 30 days of the onset of anemia. Attributable leucopenia was defined as the use of mycophenolate at least for 14 days prior to a leucocyte count <3 G/L and/or initiation of granulocyte colony stimulating factor or granulocytemacrophage colony stimulating factor therapy within 30 days of the onset of leucopenia. 
SNP selection and identification of genotypes
Statistical analysis
The statistical analyses were performed using R software version 2. 
Results
Clinical data
The characteristics of the 189 patients included in this pharmacogenetic sub-study are presented in Table 1 . A total of 46 (27%) patients were diagnosed with BPAR, out of 168 patients with such data available. Eight patients had 2 BPAR events, which led to a total of 54 BPAR episodes. The 21 patients with no biopsy results were completely at random. A total of 15 (8.6%) patients out of the 189 patients had at least one diarrhea episode. Among them, 2 patients had 2 diarrhea events, which led to a total of 17 diarrhea episodes. Twenty three episodes of leucopenia were found in 19 patients, among the 1398 data available over 9 visits.
A hundred seventy five episodes of anemia were found in 98 patients, among the 1279 data available over 9 visits. In the present substudy, 9 patients (9.6%) in the steroid avoidance group were actually given corticosteroids in the course of the study, based on clinician decision. All the SNPs respected the Hardy Weinberg equilibrium.
BPAR and pharmacogenetic associations
No significant association was found between SNP, age, sex, randomization group, CD EC-MPS , AUC C2 and BPAR in univariate or multivariate analysis (Table 2) .
Diarrhea and pharmacogenetic associations
Univariate analysis showed that no genetic covariate was significantly associated with diarrhea ( 
Anemia and pharmacogenetic associations
Univariate analysis of anemia ( 
Discussion
This study investigating potential associations between polymorphisms in target, metabolism or transport proteins of mycophenolate sodium and drug-related clinical events in kidney transplant recipients. The result showed that there was no association between any SNP or EC-MPS dose on BPAR, there was a significant influence of: female gender on the risk of diarrhea; CYP2C8 rs11572076 G>A on leucopenia and UGT2B7 c.-840 G>A variant allele and EC-MPS dose on anemia.
In the present study, patient exposure to the immunosuppressants was taken into account as the time-weighted mean value (AUC of (EC-MPS dose or cyclosporine C2) per time unit).
This approach is not common and has not been, to our knowledge, applied and validated previously. Usually, to take into account the level of immunosuppression, authors test the effect of CsA C2 or EC-MPS dose at each protocol visit. However, it increases the number of tests and thus the alpha risk, and it considers each period independently, so that the influence of slight underexposure or overexposure for long periods of time will not be detected. In the present study, no association was found between CsA C2 and BPAR. As already mentioned above, a limitation may be that such an exposure index obviously averages local variations. It seems that initial studies showed a benefit of C2 monitoring; however, recent studies questioned this benefit [18] .
In the present ancillary study, we considered BPAR and borderline lesions together, which partly explains the high percentage of BPAR obtained. When we consider only acute rejection, there were 37 episodes (=22%), but this is still quite high and we have no explanation for this. We cannot exclude a selection bias by which clinicians would have encouraged more patients with rejection to participate in this pharmacogenetic substudy. Such a selection bias, if any, would increase the statistical power of our tests but would not bias the gene-outcome association found. .
Stern et al reported that female Sprague-Dawley rats treated chronically with oral MPA had more GI toxicity than male rats and that intestinal microsomes from the upper jejunum of the female rats had 3-fold lower MPA glucuronidation rates than males [19] . The authors made the hypothesis that the greater susceptibility of female rats to diarrhea could thus result from reduced protection of enterocytes by in situ glucuronidation. This is consistent with the present finding of a significant association between female gender and increased risk of diarrhea. A possible limitation to this finding is that different attitudes of females and males with respect to diarrhea declaration to the physician could have led to a false association between diarrhea and sex. However, by choosing a conservative definition of diarrhea (requiring EC-MPS dose reduction or prolonging hospitalization), we hope we minimized this reporting bias, if any. Such an effect of sex on diarrhea was not found in the princeps study and in the clinical trials with EC-MPS [1, 17, 20] , maybe because it was not investigated, or maybe because it is a spurious result here. It would be of interest to analyze in more detail the results of previous trials to confirm or turn down this apparent association. It must also be admitted that it could be chance finding in our study, owing to an imbalance between the different risk factors of diarrhea between males and females. In any case, we do not think that this finding could lead to clinical recommendations.
The CYP2C8 rs11572076 variant allele has been previously associated with an increased risk of leucopenia in the fixed dose arm of the FDCC study [16] . This may be partly influenced by a decreased of MPA metabolism associated to the CYP2C8 variant allele and to a higher exposure to MPA, which is well known to favor leucopenia [21] . However, it is rather unlikely that this SNP could explain on its own such an increased in MPA exposure given the minor involvement of this enzyme in MPA metabolism [22] . It is of note that there was no difference in EC-MPS dose between CYP2C8 genotype groups (data not shown), as confirmed by the non-significant statistical interaction between the CYP2C8 SNP and EC-MPS dose.
In contrast to the results reported by Jacobson et al. [15] , no effect of HUS1 on anemia was observed. The major difference between their study and the present one was the galenic form of mycophenolate (EC-MPS vs. MMF), but it may not be sufficient to explain this discrepancy. Another possible explanation could be an insufficient statistical power in the present study to detect such an effect on anemia. However, another group did not observe any impact of this polymorphism on anemia despite a larger group of renal transplant patients [16] .
An increasing risk of anemia was found with increasing doses of EC-MPS. These results are in conformity with one of the phase 3 MMF studies, which found that MMF dosing was related to anemia [23] . In this study, we also found an increased risk of anemia in carriers of the UGT2B7 c. A general limitation of this study is that MPA exposure was not measured. Indeed, the EC-MPS formulation is associated with a higher intra-and inter-patient variability in MPA exposure than MMF at equivalent doses [1, 27] . Thus, EC-MPS dose cannot be considered the best marker of MPA exposure.
In conclusion, in a population of 189 renal transplant patients treated with EC-MPS, two pharmacogenetic associations previously reported with MMF were found. The clinical implementation of pharmacogenetic markers would be of particular interest for this particular formulation, which has a hardly predictable pharmacokinetics. However, it is premature to recommend such genotyping in routine practice because the exact mechanisms behind these findings are still unclear. These results have to be confirmed by independent studies. 2 (1%) * (mean C2)×follow-up duration ; **(mean EC-MPS dose)×the follow-up period duration; $ diarrhea episodes leading to EC-MPS dose reduction or prolonged hospitalization; for BPAR and diarrhea, the first episode was taken into account, for anemia and leucopenia, the total number of events among the whole protocol visits were taken into account. 
